top of page
Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
- Aug 31, 2022
Alpha Tau Medical to Participate in Upcoming September Investor Conferences
JERUSALEM, August 30, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the Company will participate in person at three upcoming investor conferences in September 2022. Additional information can be found on the Events and Presentations section of Alpha Tau’s investor website, www.alphatau.com/events. If you would like to schedule a 1:1 meeting, please contact the appropriat
- Aug 26, 2022
Alpha Tau Medical Announces Second Quarter 2022 - Financial Results and Provides Corporate Update
-Received FDA Conditional Investigational Device Exemption (IDE), whose conditions have since been satisfied, to initiate a pivotal trial of Alpha DaRT™ in recurrent cutaneous squamous cell carcinoma. The Company expects to treat its first patient in this study later in 2022- -Treated first patient in a feasibility study evaluating the Alpha DaRT as a neoadjuvant therapy in patients with prostate cancer- JERUSALEM, August 25, 2022 - Alpha Tau Medical Ltd. (Nasdaq: DRTS and DR
- Aug 22, 2022
Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning
JERUSALEM and CLEVELAND, Aug. 22, 2022 -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and MIM Software Inc. (“MIM Software”), a leading global provider of medical imaging software, announced a collaboration between the two companies to provide treatment planning software for clinical sites using the Alpha DaRT therapy. Under the terms of the agreement, the parties will collaborate on
bottom of page